|Bid||432.90 x 3000|
|Ask||433.00 x 1000|
|Day's range||426.61 - 453.60|
|52-week range||65.49 - 497.49|
|Beta (5Y monthly)||1.48|
|PE ratio (TTM)||50.82|
|Earnings date||27 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||326.00|
Moderna (NASDAQ: MRNA) has been a huge winner so far this year with its share price more than quadrupling. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not now is a good time to buy Moderna stock. Keith Speights: Bhakti asks, "Is it a good time to initiate a position in Moderna?" MRNA is the ticker there.
Shares of Moderna (NASDAQ: MRNA) have soared more than 300% since the beginning of the year. Earlier this year, investors watched Moderna become profitable after one full quarter of coronavirus vaccine sales. The picture ahead looks bright for Moderna.
Wolfgang Puck, Chef & Restaurateur, joins Yahoo Finance to discuss the CUT NYC’s new outdoor dining space 'The CUT Terrace' at Four Seasons Hotel New York Downtown, outlook on staffing in the restaurant industry, and NYC”s vaccine mandate for restaurants.